Gastrointestinal Drug Maker Soars 162% on New Patent

Good Afternoon! 

Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today.

Every strong portfolio starts with a reliable core — and this new report may help investors build exactly that.

“7 Stocks to Buy and Hold Forever” highlights a group of companies with a track record of steady performance, strong fundamentals, and long-term growth potential.

For a limited time, this full report is being offered at no cost.

These stocks were chosen for a reason — and could help lay the groundwork for a strategy built to outlast short-term swings.

[Access the report free here]

U.S. stocks rose today as Nvidia’s surge to a $4 trillion valuation boosted the tech sector and offset concerns over escalating tariffs, while hopes for a trade deal with the EU helped ease investor anxiety.

Merck (NYSE: MRK) is acquiring Verona Pharma for $10 billion, adding a commercial-stage COPD treatment as it moves to offset upcoming revenue erosion from Keytruda’s patent expirations.

The inhaled drug, Ohtuvayre, was recently approved and is expected to generate peak annual sales of $3 to $4 billion by the 2030s, according to analyst projections.

Verona marks Merck’s largest deal since its 2023 acquisition of Prometheus Biosciences, continuing a trend of targeted expansion in the respiratory and immunology sectors.

As patent cliffs approach, Merck is prioritizing assets with near-term impact and long-term category growth.

Existing shareholders may view the Verona acquisition as an attempt to reduce concentration risk without sacrificing margin potential.

By targeting assets with known upside and immediate revenue contribution, Merck is building defensible income streams while preserving room for further expansion.

Those evaluating a new position may find Merck’s evolving capital deployment strategy worth attention.

The Verona deal comes with limited integration risk, fits within Merck’s preferred transaction range, and shows clear alignment with its broader pipeline shift.

Once finalized, the all-cash deal will bring Ohtuvayre fully under Merck’s commercial umbrella, with integration expected later this year pending regulatory approval.

As we dive into Q2 2025, the stock market is buzzing with opportunities, and I’ve got the insider scoop just for you.

I’ve handpicked the Top Seven Stocks for this quarter, offering you a clear roadmap for growth as the year progresses.

Here’s what makes this guide indispensable:

This isn’t merely a list; it’s your chance to seize the market’s hottest opportunities before they pass you by.

[Get Your Free Guide Now]

Nvidia (NASDAQ: NVDA) has become the world’s first publicly traded company to reach a $4 trillion market valuation, outpacing Microsoft and Apple in the process.

This milestone marks a pivotal moment in the global AI race, as demand for Nvidia’s GPUs continues to surge across data centers, cloud platforms, and autonomous tech infrastructure.

The company’s latest revenue report showed more than $44 billion generated last quarter, with expectations of maintaining that momentum in the current quarter.

That scale has positioned Nvidia at the heart of the AI supply chain, powering systems for industry leaders including Microsoft, Amazon, and Google.

For long-term holders, the milestone reflects Nvidia’s firm grip on the compute layer of global AI expansion.

The company’s lead in foundational chips has translated into platform stickiness, strong demand visibility, and increasing wallet share from hyperscalers.

That level of embeddedness offers margin stability that’s rare in high-growth names.

Those watching Nvidia for a potential entry point may view this phase as a validation of durable pricing power.

While the valuation sets a high bar, the company’s role as an AI arms dealer rather than just an end-product brand makes its standing difficult to replicate.

Any material pullback could reframe the name as a structural compounder rather than a short-term momentum trade.

Starting this July, big banks can legally treat gold as cash—and they’re wasting no time.

Meanwhile, millions of Americans are still heavily invested in volatile paper assets.

One economist says gold is now “the only money banks trust.”

There’s still time to catch up, using an IRS-approved method that avoids taxes or penalties.

This FREE Wealth Protection Guide explains how to move before the window closes.

[Click here to access the guide]

P.S. Every day you wait, the insiders move further ahead. Get the facts before July hits.

After a brutal first half of the year, UnitedHealth (NYSE: UNH) is attracting some unexpected buyers, including members of Congress.

The stock has fallen more than 40 percent year-to-date, hit by a cybersecurity breach, government scrutiny, and a leadership shuffle.

Yet even as shares remain stuck near $300, signs of a rebound are starting to appear from within the company itself.

New management has stepped in, and multiple senior executives have increased their stakes since June.

Congressional trading data also shows select politicians building positions around the same time.

These kinds of overlapping signals suggest internal conviction that the worst may be over.

The Valuation Gap Is Getting Harder to Ignore

UnitedHealth now trades at a price-to-earnings ratio of just 12.65, which is unusually low for a business with its historical growth and market dominance.

Analysts covering the stock have set a consensus price target of $415, implying a potential upside of nearly 37% from current levels.

The stock also offers a dividend yield of 2.92 percent, providing an additional buffer for investors taking a position at these lower levels.

Leadership Reset Is a Key Catalyst

The shakeup in management has already started to reshape sentiment.

With new executives and the cybersecurity crisis mostly behind them, the company appears focused on stabilizing operations and rebuilding credibility with shareholders.

Wall Street remains divided for now, but insider buying often leads public opinion.

The fact that both insiders and congressional buyers are moving in this early may reflect confidence in the long-term outlook, even if the near-term picture remains cloudy.

When Insiders Act, the Market Usually Follows

Institutions often move more slowly than insiders, which gives early buyers a window.

UnitedHealth's price collapse has drawn attention, but insider accumulation suggests value under the surface. 

Investors seeking a long-term recovery story, combined with defensive sector exposure and dividend support, may want to revisit this name while it remains trading at a discount.

👉 Click here to get our closing report to your cell for free!

Evoke Pharma [EVOK] $6.98 (+162.77%)

Evoke Pharma surged after securing a new U.S. patent for GIMOTI use in moderate-to-severe gastroparesis, extending market exclusivity through 2036.

Artelo Biosciences Inc [ARTL] $21.60 (+35.85%)

Artelo rose after presenting promising preclinical data showing its novel non-opioid candidate ART26.12 relieved osteoarthritis pain without tolerance buildup.

Rhythm Pharmaceuticals Inc [RYTM] $89.00 (+35.20%)

Rhythm Pharmaceuticals soared on strong Phase 2 results showing its MC4R-targeting drug significantly reduced BMI in patients with acquired hypothalamic obesity.

Bitmine Immersion Technologies Inc [BMNR] $66.71 (-40.17%)

BMNR plunged as investors reacted negatively to its $250 million Ethereum treasury pivot, as the company previously focused on Bitcoin.

RxSight Inc [RXST] $7.95 (-37.84%)

RxSight fell after issuing weaker-than-expected Q2 results and slashing full-year revenue guidance, despite higher margins.  

Thumzup Media Corp [TZUP] $9.50 (-23.14%)

Thumzup Media dropped sharply after closing a discounted stock offering, raising dilution concerns despite its expanding crypto accumulation strategy.

While headlines focus on the same overhyped AI names, a bigger opportunity is taking shape — and it’s flying under the radar.

A new report reveals 9 AI companies with real U.S. operations, accelerating revenue, and deep AI integration. These aren’t speculative plays — they’re positioned to benefit from a massive shift in how and where AI is being built.

This free guide includes:

…plus 6 more names with major upside potential.

The early window on these opportunities may be closing — now’s the time to see what’s coming next.

[Get your FREE copy now]

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.